93 related articles for article (PubMed ID: 8610821)
1. Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms.
Wolkin A; Sanfilipo M; Duncan E; Angrist B; Wolf AP; Cooper TB; Brodie JD; Laska E; Rotrosen JP
Am J Psychiatry; 1996 Mar; 153(3):346-54. PubMed ID: 8610821
[TBL] [Abstract][Full Text] [Related]
2. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.
Bartlett EJ; Brodie JD; Simkowitz P; Schlösser R; Dewey SL; Lindenmayer JP; Rusinek H; Wolkin A; Cancro R; Schiffer W
Am J Psychiatry; 1998 Mar; 155(3):337-43. PubMed ID: 9501742
[TBL] [Abstract][Full Text] [Related]
3. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol.
Holcomb HH; Cascella NG; Thaker GK; Medoff DR; Dannals RF; Tamminga CA
Am J Psychiatry; 1996 Jan; 153(1):41-9. PubMed ID: 8540590
[TBL] [Abstract][Full Text] [Related]
4. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients.
Siegel BV; Buchsbaum MS; Bunney WE; Gottschalk LA; Haier RJ; Lohr JB; Lottenberg S; Najafi A; Nuechterlein KH; Potkin SG
Am J Psychiatry; 1993 Sep; 150(9):1325-36. PubMed ID: 8352343
[TBL] [Abstract][Full Text] [Related]
5. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia.
Buchsbaum MS; Potkin SG; Siegel BV; Lohr J; Katz M; Gottschalk LA; Gulasekaram B; Marshall JF; Lottenberg S; Teng CY
Arch Gen Psychiatry; 1992 Dec; 49(12):966-74. PubMed ID: 1449383
[TBL] [Abstract][Full Text] [Related]
6. Low frontal glucose utilization in chronic schizophrenia: a replication study.
Wolkin A; Angrist B; Wolf A; Brodie JD; Wolkin B; Jaeger J; Cancro R; Rotrosen J
Am J Psychiatry; 1988 Feb; 145(2):251-3. PubMed ID: 3257653
[TBL] [Abstract][Full Text] [Related]
7. Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia.
Bartlett EJ; Wolkin A; Brodie JD; Laska EM; Wolf AP; Sanfilipo M
Psychiatry Res; 1991 Oct; 40(2):115-24. PubMed ID: 1763142
[TBL] [Abstract][Full Text] [Related]
8. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo.
Gründer G; Vernaleken I; Müller MJ; Davids E; Heydari N; Buchholz HG; Bartenstein P; Munk OL; Stoeter P; Wong DF; Gjedde A; Cumming P
Neuropsychopharmacology; 2003 Apr; 28(4):787-94. PubMed ID: 12655326
[TBL] [Abstract][Full Text] [Related]
9. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes.
Arango C; Breier A; McMahon R; Carpenter WT; Buchanan RW
Am J Psychiatry; 2003 Aug; 160(8):1421-7. PubMed ID: 12900303
[TBL] [Abstract][Full Text] [Related]
10. Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients.
Martinot JL; Peron-Magnan P; Huret JD; Mazoyer B; Baron JC; Boulenger JP; Loc'h C; Maziere B; Caillard V; Loo H
Am J Psychiatry; 1990 Jan; 147(1):44-50. PubMed ID: 2293788
[TBL] [Abstract][Full Text] [Related]
11. Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia.
Volkow ND; Wolf AP; Van Gelder P; Brodie JD; Overall JE; Cancro R; Gomez-Mont F
Am J Psychiatry; 1987 Feb; 144(2):151-8. PubMed ID: 3492931
[TBL] [Abstract][Full Text] [Related]
12. Correlates of lateral ventricular size in chronic schizophrenia, I: Behavioral and treatment response measures.
Losonczy MF; Song IS; Mohs RC; Small NA; Davidson M; Johns CA; Davis KL
Am J Psychiatry; 1986 Aug; 143(8):976-81. PubMed ID: 3524278
[TBL] [Abstract][Full Text] [Related]
13. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography.
Wolkin A; Jaeger J; Brodie JD; Wolf AP; Fowler J; Rotrosen J; Gomez-Mont F; Cancro R
Am J Psychiatry; 1985 May; 142(5):564-71. PubMed ID: 3872603
[TBL] [Abstract][Full Text] [Related]
14. Familial schizophrenia and treatment response.
Silverman JM; Mohs RC; Davidson M; Losonczy MF; Keefe RS; Breitner JC; Sorokin JE; Davis KL
Am J Psychiatry; 1987 Oct; 144(10):1271-6. PubMed ID: 3661762
[TBL] [Abstract][Full Text] [Related]
15. Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia.
Szechtman H; Nahmias C; Garnett ES; Firnau G; Brown GM; Kaplan RD; Cleghorn JM
Arch Gen Psychiatry; 1988 Jun; 45(6):523-32. PubMed ID: 2897836
[TBL] [Abstract][Full Text] [Related]
16. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
[TBL] [Abstract][Full Text] [Related]
17. Risperidone in the treatment of schizophrenia.
Marder SR; Meibach RC
Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
[TBL] [Abstract][Full Text] [Related]
18. Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients.
Smith M; Wolf AP; Brodie JD; Arnett CD; Barouche F; Shiue CY; Fowler JS; Russell JA; MacGregor RR; Wolkin A
Biol Psychiatry; 1988 Apr; 23(7):653-63. PubMed ID: 2967093
[TBL] [Abstract][Full Text] [Related]
19. Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients.
Czobor P; Volavka J
J Clin Psychopharmacol; 1993 Oct; 13(5):332-42. PubMed ID: 7693770
[TBL] [Abstract][Full Text] [Related]
20. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia.
Convit A; Volavka J; Czobor P; de Asis J; Evangelista C
Am J Psychiatry; 1994 Jan; 151(1):49-56. PubMed ID: 8267134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
